Zuranolone
Zuranolone is a prescription medication specifically approved for the treatment of postpartum depression (PPD) in adults. It works by positively modulating GABA A receptors in the brain, which is believed to help alleviate depressive symptoms associated with PPD. The medication is typically taken orally for a limited duration as directed by a healthcare provider.
Zuranolone is a GABA A receptor modulator approved for treating postpartum depression in adults.
This medication carries a boxed (black box) warning — the strongest type of FDA warning. Review the full prescribing information before use.
Key facts at a glance
- ATC
- N06AX31
- RxNorm
- 2669905
- Generic
- Zuranolone
- Class
- atc-n06
- Brands
- Zurzuvae
- Availability
- rx
- Lactation
- unknown
- Routes
- oral
- Forms
- capsule
- Regions
- US, EU, CN, JP
- Monitoring
- —
This page is for informational purposes only.
Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.
Zuranolone is indicated for the treatment of postpartum depression (PPD) in adults. PPD is a type of major depressive disorder that occurs during pregnancy or after childbirth, characterized by persistent feelings of sadness, anxiety, exhaustion, and difficulty bonding with the baby.
Zuranolone acts as a positive allosteric modulator of gamma-aminobutyric acid type A (GABA A) receptors in the brain. By enhancing GABAergic signaling, it helps reduce neuronal excitability. While the exact mechanism for its therapeutic effect in PPD is not fully understood, this modulation of GABA receptors is believed to contribute to its antidepressant effects.
Zuranolone may cause drowsiness and impair ability to drive or operate machinery. It should be used with caution in patients with hepatic or renal impairment. The medication is not recommended for use during breastfeeding unless clearly needed. Patients should inform their healthcare provider of all medications they are taking to avoid potential drug interactions. Treatment duration and dosing should follow the prescribing healthcare provider's instructions.
Official drug label
WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed July 26, 2026. · Read our editorial policy